Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2020

  1. 18/03/2020
    MorphoSys Presents Results for Fiscal Year 2019
  2. 12/03/2020
    Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020
  3. 04/03/2020
    MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation
  4. 03/03/2020
    MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab
  5. 02/03/2020
    FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
  6. 04/02/2020
    MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
  7. 13/01/2020
    MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
  8. 13/01/2020
    MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
    No download available

2019

  1. 30/12/2019
    MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
  2. 27/12/2019
    First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2018

  1. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  2. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  3. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  4. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
  5. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available
  2. 23/10/2017
    Ad hoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
    No download available
  3. 21/07/2017
    Ad hoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
    No download available
  4. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement

Pages

Presentations
and conferences

Thursday, June 18, 2020
Webcast: JMP Securities Hematology and Oncology Forum

Dr. Jean-Paul Kress presented the Company at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020.

Date: June 18, 2020, 11:40am EDT (5:40pm CEST)

Go to Webcast...

Archive

Date
Title
MP3

2020

  1. 06/18/2020

    Webcast: JMP Securities Hematology and Oncology Forum

  2. 06/10/2020

    Webcast: Goldman Sachs 41st Annual Global Healthcare Conference

  3. 06/03/2020

    Webcast: Jefferies 2020 Healthcare Conference

  4. 05/07/2020

    Conference Call and Webcast: Q1 2020 Financial Results

  5. 03/19/2020

    Conference Call and Webcast: Year End 2019

  6. 02/26/2020

    Webcast: 9th Annual SVB Leerink Global Healthcare Conference

  7. 01/15/2020

    Webcast: 38th Annual J.P. Morgan Healthcare Conference

  8. 01/13/2020

    Joint Conference Call MorphoSys and Incyte on the Global Collaboration and License Agreement for Tafasitamab

2019

  1. 12/03/2019

    31st Annual Piper Jaffray Healthcare Conference

  2. 11/25/2019

    Presentation: German Eigenkapitalforum

  3. 10/30/2019

    Conference Call and Webcast: Q3 2019 Financial Results

  4. 09/25/2019

    Presentation: 8th Annual Goldman Sachs and Berenberg German Corporate Conference

  5. 08/27/2019

    Presentation: Commerzbank Sector Conference 2019

  6. 08/07/2019

    Conference Call and Webcast: Q2 2019 Financial Results

Pages

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".